Leukaemia Foundation and HSANZ Jointly Funds Three PhD Investigators
Thursday, 8 November 2018
The Leukaemia Foundation and the Haematology Society of Australia and New Zealand (HSANZ) are proud to announce the co-funding of three Australian Clinical and Science PhD investigators, whose work will focus on understanding blood cancer biology and the development of new diagnostics and precision medicines.
Position Statement: Glyphosate
Updated 17 June 2019
The Leukaemia Foundation’s CEO Bill Petch said the Leukaemia Foundation had been closely monitoring the issue of glyphosate for many years. It accepts the position of the APVMA as the Australian regulatory body, however, as the last review was undertaken in early 2017, we encourage the
Leukaemia Foundation supports WEHI’s new laboratory model to test anti-cancer drugs
Tuesday, 16 October 2018
A new model which mimics the complexity of human cancers to allow for more accurate testing of anti-cancer drugs has been developed by leading Australian researchers at the Walter and Eliza Hall Institute (WEHI) in Melbourne.
Led by PhD students Ms Margs Brennan and Dr Gemma Kelly
Leukaemia Foundation supports Health Minister’s call to introduce ground breaking CAR-T Cell therapies into Australian Public Hospitals
Tuesday, 16 October 2018
The Leukaemia Foundation has come out in support of today’s call by Federal Health Minister Greg Hunt to fast track the revolutionary CAR T-Cell therapy into Australian hospitals.
CAR-T cell therapy involves harvesting a patient’s T-cells, a type of immune cell, and genetically engineering them to attack
Congratulations to Nobel Prize immunotherapy pioneers
Thursday, 04 October 2018
The Leukaemia Foundation congratulates the 2018 Nobel Prize in Medicine winners, James Allison of the US and Tasuku Honjo of Japan, for their research and discovery into how the body’s natural defences can fight cancer such as lymphoma.
“As Australia’s leading blood cancer organisation, we acknowledge the
Follicular lymphoma and multiple myeloma treatment now available to Australians through $48m PBS listing
Monday, 01 October 2018
The Leukaemia Foundation welcomes the Federal Government’s announcement confirming new medicine for both follicular lymphoma and multiple myeloma will be added to Pharmaceutical Benefits Scheme (PBS) from 1 October 2018.
Leukaemia Foundation CEO Bill Petch said the PBS listing of Gazyva (obinutuzumab) would benefit around 700 people
Lymphoma and myeloma treatments to be subsidised through $48m PBS listing
The Leukaemia Foundation has applauded the Federal Government’s recent announcement of funding $48 million towards more affordable drugs for Australians living with blood cancer.
Leukaemia Foundation CEO Bill Petch said the Pharmaceutical Benefits Scheme (PBS) listing of Gazyva (obinutuzumab) this October
Unprecedented funds for cutting-edge research into myeloma
Australian researchers will share in $10 million of funding toward developing groundbreaking treatments to help people living with rare cancers and diseases, including myeloma.
The funding will be shared across six clinical trials and will be conducted by researchers at Monash
Australians urged to seek support this World Lymphoma Awareness Day
Friday, 14 September 2018
Australians living with lymphoma are surviving more but experiencing a fear of relapse, anxiety, depression and isolation according to a recent report.
And despite survival rates jumping from just 52 per cent in the early 1980s to 76 per cent today, those diagnosed in regional Australia are
Leukaemia Foundation continues to fight for Australians living with blood cancer
Friday, 07 September 2018
September is Blood Cancer Awareness Month
Every day another 35 Australians are diagnosed with a blood cancer or disorder, and according to the latest analysis from the Leukaemia Foundation, this number continues to rise. Leukaemia, lymphoma and myeloma and the blood disorder myelodysplastic syndrome (MDS) are four